Trifluridine
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Trifluridine |
| DrugBank ID | DB00432 |
| Brand Names (EU) | Trifluridine |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 98.86% |
Approved Indication (EMA)
Colorectal cancer Lonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (CRC) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and/or anti-EGFR agents. Lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | colonic neoplasm | 98.86% | DL |
| 2 | cecum villous adenoma | 98.60% | DL |
| 3 | lipoma of colon | 98.59% | DL |
| 4 | colonic lymphangioma | 98.57% | DL |
| 5 | cecum neuroendocrine tumor G1 | 98.56% | DL |
| 6 | rectosigmoid junction neoplasm | 98.56% | DL |
| 7 | colon leiomyoma | 98.56% | DL |
| 8 | cecal disease | 98.54% | DL |
| 9 | benign neoplasm of cecum | 98.52% | DL |
| 10 | cavernous hemangioma of colon | 98.46% | DL |
| 11 | squamous cell carcinoma of colon | 97.61% | DL |
| 12 | photosensitivity disease | 97.33% | DL |
| 13 | common wart | 96.69% | DL |
| 14 | malignant colon neoplasm | 96.21% | DL |
| 15 | colorectal gastrointestinal stromal tumor | 95.79% | DL |
| 16 | colorectal leiomyoma | 95.79% | DL |
| 17 | colon carcinoma in situ | 95.77% | DL |
| 18 | colorectal hamartoma | 95.72% | DL |
| 19 | rectosigmoid carcinoma | 95.70% | DL |
| 20 | colon small cell neuroendocrine carcinoma | 95.50% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.